Discover 1,070 paid clinical trials in Ogden, Utah. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,070
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
Location: Salt Lake City UT, Duarte CA, Stanford CA, Portland OR,
Sponsor: Jasper Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT04429191
Phase1, Recruiting
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
for
Cutaneous Melanoma, Brain Metastases
Location: Salt Lake City UT, Iowa City IA
Sponsor: University of Utah
Sex: All
Age: 18+
Code: NCT06194929
Phase1, Phase2, Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
for
Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme,
Location: Salt Lake City UT, Scottsdale AZ, Los Angeles CA,
Sponsor: Tango Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06810544
Phase1, Phase2, Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
for
Metastatic Solid Tumor, Advanced Solid Tumor
Location: Salt Lake City UT, West Valley City UT, Aurora CO,
Sponsor: Coherus Oncology, Inc.
Sex: All
Age: 18+
Code: NCT06657144
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
for
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified,
Location: Salt Lake City UT
Sponsor: Academic and Community Cancer Research United
Sex: All
Age: 18+
Code: NCT06238648
Phase2, Recruiting
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
for
Advanced Lung Neuroendocrine Tumor,
Location: Salt Lake City UT, Los Angeles CA, Beverly Hills CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04665739
Phase2, Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: Salt Lake City UT, Santa Fe NM, Clovis CA, Gilbert AZ,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT05552222
Phase3, Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
for
Superficial Bladder Cancer,
Location: Salt Lake City UT, Lakewood CO, Scottsdale AZ,
Sponsor: enGene, Inc.
Sex: All
Age: 18+
Code: NCT04752722
Phase1, Phase2, Recruiting
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
for
Chronic Myeloid Leukemia, Chronic Phase,
Location: Salt Lake City UT, Lone Tree CO, Gilbert AZ, Eugene OR,
Sponsor: Terns, Inc.
Sex: All
Age: 18+
Code: NCT06163430
Phase1, Phase2, Recruiting
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
for
Advanced Solid Tumors
Location: Salt Lake City UT, Houston TX, Cincinnati OH
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
Sex: All
Age: 18+
Code: NCT06096974
Phase1, Recruiting
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
for
Metastatic Digestive System Neuroendocrine Tumor G1,
Location: Salt Lake City UT, Aurora CO, Albuquerque NM,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05773274
Phase2, Recruiting
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
for
Breast Cancer Recurrent
Location: Salt Lake City UT
Sponsor: University of Utah
Sex: All
Age: 18+
Code: NCT05464082
Phase2, Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
for
Advanced Melanoma
Location: Salt Lake City UT, Murray UT, Englewood CO, Aurora CO,
Sponsor: Replimune, Inc.
Sex: All
Age: 12+
Code: NCT06264180
Phase3, Recruiting
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
for
AIDS-Related Diffuse Large B-cell Lymphoma,
Location: Salt Lake City UT, Duarte CA, Chicago IL, Columbus OH,
Sponsor: AIDS Malignancy Consortium
Sex: All
Age: 18+
Code: NCT05077527
Phase1, Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for
Carcinoma, Non-Small-Cell Lung
Location: Salt Lake City UT, Lone Tree CO, Albuquerque NM,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06667076
Phase2, Recruiting
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
for
Angioimmunoblastic T-cell Lymphoma,
Location: Salt Lake City UT, Walla Walla WA, Los Angeles CA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT04803201
Phase2, Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
for
Breast Cancer
Location: Salt Lake City UT, Glendale AZ, Phoenix AZ,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07062965
Phase3, Recruiting
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
for
Plasma Cell Leukemia
Location: Salt Lake City UT, Buffalo NY
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT07605416
Phase2, Recruiting
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer